IOL Chemicals & Pharmaceuticals Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/11fhtr98z0y8480u51ebrxj5.pdf

Key Takeaways


Pharma: The Growth Engine

Chaturvedi: "The good news is that we've got the right tools to play with. We've got the right products. We've got the right approvals. We've got the right team who's talking to the right set of customers, and now it's a question of time before you start to see the commercial benefit of all this."

Chemicals: Bottoming Out


Pricing & Input Costs

Chaturvedi: "I'm not sure that's necessarily true. And what I'd like you to do is take a look at not just the price realization, but the profit realization because I think the question to be asked is if my peers and competitors are selling at a higher price, why are they not more profitable?"

Regulatory & IP Milestones


Strategy & Capital Allocation

Chaturvedi: "I will say that a specialty chemicals and an API business is a lot like an iceberg. The financial numbers that you see don't quite articulate the holds of employees and other stakeholders that actually enable these numbers."

Industry Context & Margin Trajectory

Chaturvedi: "And in this industry, business improvement happens in years, not in quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
Chemical division profitabilityReturn to profitability after high-cost inventory and maintenance downtime clearQ4 FY23
Non-ibuprofen salesExceed ₹500 croresThis year (FY23)
Non-ibuprofen segment profitabilityEntire segment turns profitable"Next coming quarters"
Ibuprofen pricingNo decline anticipated from current $11–$12/kg export rangeOngoing
Ibuprofen capacity utilizationReach 95% peak utilization"Another few quarters"
Paracetamol capacity utilizationReach 90%One year down the line
Western India investmentPostponed given macro environment; current facility sufficient for growthAt least next year or so
Regulated market commercial benefitRevenue from CEPs and EU GMP approvals"A few more quarters"

Key Metrics

MetricQ3 FY23
Total income₹530 cr, vs ₹564 cr YoY and ₹546 cr QoQ
EBITDA₹49.7 cr, vs ₹68.1 cr YoY and ₹36.7 cr QoQ
EBITDA margin9.4%, vs 6.8% QoQ
Net profit₹24 cr, vs ₹40 cr YoY and ₹15.7 cr QoQ
Exports (9M FY23)₹431 cr, grew 26% YoY from ₹368 cr
Net cash~₹300 cr as of December 2022
Ibuprofen export pricing$11–$12/kg, stable; India prices slightly lower
Ibuprofen capacity utilizationNorth of 80%, expected to improve further
Non-Ibuprofen API revenue (FY23E)~₹500 cr, delivered in 9M what it did in full FY22
Chemical capacity utilizationWell above 95%
Ethyl acetate pricing₹83–₹84/kg, not completely flat; slightly lower QoQ
Acetic acid pricing~₹40/kg, stable
Paracetamol capacity3,600 tons, process stabilized; domestic price ₹530–₹550/kg
Paracetamol expected utilization (1 year)90%
CapEx spent (FY23)~₹150 cr, typical annual run-rate
Revenue from exports (overall)~27% of total revenue